A citation-based method for searching scientific literature

Anders Albèr, Andreas Brønden, Filip K Knop. Diabetes Obes Metab 2017
Times Cited: 5







List of co-cited articles
19 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Effects of lixisenatide once daily on gastric emptying in type 2 diabetes--relationship to postprandial glycemia.
Martin Lorenz, Claudia Pfeiffer, Axel Steinsträsser, Reinhard H A Becker, Hartmut Rütten, Peter Ruus, Michael Horowitz. Regul Pept 2013
102
60

Efficacy and Safety of Liraglutide Added to Insulin Treatment in Type 1 Diabetes: The ADJUNCT ONE Treat-To-Target Randomized Trial.
Chantal Mathieu, Bernard Zinman, Joanna Uddén Hemmingsson, Vincent Woo, Peter Colman, Erik Christiansen, Martin Linder, Bruce Bode. Diabetes Care 2016
100
60

Efficacy and Safety of Liraglutide Added to Capped Insulin Treatment in Subjects With Type 1 Diabetes: The ADJUNCT TWO Randomized Trial.
Bo Ahrén, Irl B Hirsch, Thomas R Pieber, Chantal Mathieu, Fernando Gómez-Peralta, Troels Krarup Hansen, Areti Philotheou, Sune Birch, Erik Christiansen, Thomas Jon Jensen,[...]. Diabetes Care 2016
71
60

Adding once-daily lixisenatide for type 2 diabetes inadequately controlled by established basal insulin: a 24-week, randomized, placebo-controlled comparison (GetGoal-L).
Matthew C Riddle, Ronnie Aronson, Philip Home, Michel Marre, Elisabeth Niemoeller, Patrick Miossec, Lin Ping, Jenny Ye, Julio Rosenstock. Diabetes Care 2013
220
40


Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6).
John B Buse, Julio Rosenstock, Giorgio Sesti, Wolfgang E Schmidt, Eduard Montanya, Jason H Brett, Marcin Zychma, Lawrence Blonde. Lancet 2009
40

Rapid tachyphylaxis of the glucagon-like peptide 1-induced deceleration of gastric emptying in humans.
Michael A Nauck, Guido Kemmeries, Jens J Holst, Juris J Meier. Diabetes 2011
206
40



Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome.
Marc A Pfeffer, Brian Claggett, Rafael Diaz, Kenneth Dickstein, Hertzel C Gerstein, Lars V Køber, Francesca C Lawson, Lin Ping, Xiaodan Wei, Eldrin F Lewis,[...]. N Engl J Med 2015
40


Efficacy and safety of fast-acting insulin aspart in comparison with insulin aspart in type 1 diabetes (onset 1): A 52-week, randomized, treat-to-target, phase III trial.
Chantal Mathieu, Bruce W Bode, Edward Franek, Athena Philis-Tsimikas, Ludger Rose, Tina Graungaard, Anne Birk Østerskov, David Russell-Jones. Diabetes Obes Metab 2018
44
40

Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes.
David M Nathan, Patricia A Cleary, Jye-Yu C Backlund, Saul M Genuth, John M Lachin, Trevor J Orchard, Philip Raskin, Bernard Zinman. N Engl J Med 2005
40



Pramlintide but Not Liraglutide Suppresses Meal-Stimulated Glucagon Responses in Type 1 Diabetes.
Alfonso Galderisi, Jennifer Sherr, Michelle VanName, Lori Carria, Melinda Zgorski, Eileen Tichy, Kate Weyman, Eda Cengiz, Stuart Weinzimer, William Tamborlane. J Clin Endocrinol Metab 2018
9
40




In Alzheimer's Disease, 6-Month Treatment with GLP-1 Analog Prevents Decline of Brain Glucose Metabolism: Randomized, Placebo-Controlled, Double-Blind Clinical Trial.
Michael Gejl, Albert Gjedde, Lærke Egefjord, Arne Møller, Søren B Hansen, Kim Vang, Anders Rodell, Hans Brændgaard, Hanne Gottrup, Anna Schacht,[...]. Front Aging Neurosci 2016
157
20

Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea.
David M Kendall, Matthew C Riddle, Julio Rosenstock, Dongliang Zhuang, Dennis D Kim, Mark S Fineman, Alain D Baron. Diabetes Care 2005
897
20

Incretin based drugs and the risk of pancreatic cancer: international multicentre cohort study.
Laurent Azoulay, Kristian B Filion, Robert W Platt, Matthew Dahl, Colin R Dormuth, Kristin K Clemens, Madeleine Durand, David N Juurlink, Laura E Targownik, Tanvir C Turin,[...]. BMJ 2016
61
20



Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial.
Richard E Pratley, Vanita R Aroda, Ildiko Lingvay, Jörg Lüdemann, Camilla Andreassen, Andrea Navarria, Adie Viljoen. Lancet Diabetes Endocrinol 2018
200
20


A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management.
Xavier Pi-Sunyer, Arne Astrup, Ken Fujioka, Frank Greenway, Alfredo Halpern, Michel Krempf, David C W Lau, Carel W le Roux, Rafael Violante Ortiz, Christine Bjørn Jensen,[...]. N Engl J Med 2015
697
20


The effect of glucagon-like peptide 1 on cardiovascular risk.
Jacob Sivertsen, Jaya Rosenmeier, Jens J Holst, Tina Vilsbøll. Nat Rev Cardiol 2012
111
20

Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial.
Dilan Athauda, Kate Maclagan, Simon S Skene, Martha Bajwa-Joseph, Dawn Letchford, Kashfia Chowdhury, Steve Hibbert, Natalia Budnik, Luca Zampedri, John Dickson,[...]. Lancet 2017
267
20

Advancing basal insulin replacement in type 2 diabetes inadequately controlled with insulin glargine plus oral agents: a comparison of adding albiglutide, a weekly GLP-1 receptor agonist, versus thrice-daily prandial insulin lispro.
Julio Rosenstock, Vivian A Fonseca, Jorge L Gross, Robert E Ratner, Bo Ahrén, Francis C C Chow, Fred Yang, Diane Miller, Susan L Johnson, Murray W Stewart,[...]. Diabetes Care 2014
164
20


Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses.
M A Nauck, E Homberger, E G Siegel, R C Allen, R P Eaton, R Ebert, W Creutzfeldt. J Clin Endocrinol Metab 1986
563
20

The design and discovery of lixisenatide for the treatment of type 2 diabetes mellitus.
Mikkel Christensen, Patrick Miossec, Bjarne Due Larsen, Ulrich Werner, Filip K Knop. Expert Opin Drug Discov 2014
18
20

Continuous subcutaneous delivery of exenatide via ITCA 650 leads to sustained glycemic control and weight loss for 48 weeks in metformin-treated subjects with type 2 diabetes.
Robert R Henry, Julio Rosenstock, Douglas Logan, Thomas Alessi, Kenneth Luskey, Michelle A Baron. J Diabetes Complications 2014
56
20

Effect of exenatide on cholecystokinin-induced gallbladder emptying in fasting healthy subjects.
Jutta Keller, Michael E Trautmann, Harry Haber, Lai San Tham, Tamsin Hunt, Kenneth Mace, Helle Linnebjerg. Regul Pept 2012
38
20


Cardiovascular safety of albiglutide in the Harmony programme: a meta-analysis.
Miles Fisher, Mark C Petrie, Philip D Ambery, Jill Donaldson, June Ye, John J V McMurray. Lancet Diabetes Endocrinol 2015
53
20

Postpartum reversibility of impaired incretin effect in gestational diabetes mellitus.
M Kosinski, F K Knop, L Vedtofte, J Grycewiczv, P Swierzewska, K Cypryk, T Vilsbøll. Regul Pept 2013
13
20

Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans.
M A Nauck, U Niedereichholz, R Ettler, J J Holst, C Orskov, R Ritzel, W H Schmiegel. Am J Physiol 1997
509
20

Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial.
Andrew J Ahmann, Matthew Capehorn, Guillaume Charpentier, Francesco Dotta, Elena Henkel, Ildiko Lingvay, Anders G Holst, Miriam P Annett, Vanita R Aroda. Diabetes Care 2018
164
20


The physiology of glucagon-like peptide 1.
Jens Juul Holst. Physiol Rev 2007
20

Effect of GLP-1 on lipid metabolism in human adipocytes.
M L Villanueva-Peñacarrillo, L Márquez, N González, M Díaz-Miguel, I Valverde. Horm Metab Res 2001
77
20

Incretins, insulin secretion and Type 2 diabetes mellitus.
T Vilsbøll, J J Holst. Diabetologia 2004
288
20


Incretin-based therapies for the treatment of non-alcoholic fatty liver disease: A systematic review and meta-analysis.
Laura J Carbone, Peter W Angus, Neville D Yeomans. J Gastroenterol Hepatol 2016
54
20

Insulin Degludec/Liraglutide: A Review in Type 2 Diabetes.
Sarah L Greig, Lesley J Scott. Drugs 2015
15
20

Efficacy and Safety of ITCA 650, a Novel Drug-Device GLP-1 Receptor Agonist, in Type 2 Diabetes Uncontrolled With Oral Antidiabetes Drugs: The FREEDOM-1 Trial.
Julio Rosenstock, John B Buse, Rehan Azeem, Prakash Prabhakar, Lise Kjems, Holly Huang, Michelle A Baron. Diabetes Care 2018
25
20

Effects of GLP-1 in the kidney.
Jeppe Skov. Rev Endocr Metab Disord 2014
44
20


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.